## Novo Nordisk Dedicates $2 Billion to a Medication for Reducing Weight
**Principal Aspects:**
* Novo Nordisk has participated in a distinct worldwide licensing arrangement valued at $2 billion for UBT251, a weight-reduction medication created by United Biotech of China.
* UBT251 has previously been approved for medical experiments in the US for grown-ups with type 2 diabetes, those who are too heavy or fat, and sufferers with lasting kidney illness.
* In related reports, Novo Nordisk is growing the accessibility of its favored Wegovy (semaglutide) injections for sufferers paying out-of-pocket, providing it at a set rate of $499 per month at nearby drug stores.
Novo Nordisk (NVO) is making a considerable dedication to the prospect of weight-reduction managements with a distinct worldwide licensing arrangement for UBT251, a hopeful medication from United Biotech.
Regardless of the encouraging reports, stocks of Novo Nordisk, the maker of blockbuster medications like Ozempic and Wegovy, declined over 2% in pre-market trading on Monday.
Under the arrangement, the Danish pharmaceutical large will pay a preliminary $200 million in advance, with the opportunity for up to $1.8 billion in milestone payments and tiered royalties. It’s important to remember that this licensing arrangement leaves out mainland China, Hong Kong, Macau, and Taiwan.
UBT251 has acquired authorization for medical experiments in China for a variety of ailments, including type 2 diabetes, overweight/fatness, metabolic dysfunction-associated steatotic liver illness (MASLD), and lasting kidney illness. It has also been approved for experiments in the U.S. for type 2 diabetes, overweight/fatness, and lasting kidney illness.
In other growths, Novo Nordisk is making Wegovy more reachable to sufferers who are paying without insurance coverage. The injectable medication, obtainable in dosages from 0.25mg to 2.4mg, will be provided at a flat rate of $499 per month at nearby drug stores.
Previously, the $499 monthly agreement was exclusively available to Novo Care Pharmacy clients.
Toncoin (TON) Value Forecast for March 26th
